The global mesalamine market size was US$ 169.5 million in 2021. The global mesalamine market size is forecast to reach US$ 212.6 million by 2030, registering a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2022 to 2030.

Mesalamine, also known as Mesalazine, is the first-line agent used to treat active UC. It is a prescription drug that includes 5-aminosalicylic acid. It also helps cure other inflammatory bowel disorders. 

Factors Influencing the Market

• Mesalamine is considered to be safe, which is why its demand is expected to increase in the coming years. The high prevalence of Ulcerative Colitis (UC) around the world is expected to drive up demand for mesalamine. The market is also likely to grow when new products are released.
• The global mesalamine industry is seeing a surge in patient support programs, which will create a slew of new opportunities. 
• The expansion of the mesalamine market is attributed to the increasing research & development as well as rising spending in healthcare in developing countries. 
• Side effects of treatments, such as vomiting, fever, headache, stomach, and abdominal discomfort, may limit the growth of the global mesalamine market during the study period. 

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the global mesalamine market. The demand for pharmaceuticals is forecast to remain the same throughout the COVID-19 pandemic period. Moreover, governments of maximum nations are highly focused on expanding the healthcare expenditure and boosting the healthcare infrastructure. Thus, it will offer ample growth opportunities for market growth. Moreover, companies are highly investing in research and development activities due to the COVID-19 influenced growth. Thus, all of this will contribute to the growth of the global mesalamine market. 

Regional Analysis

North America is forecast to hold the largest mesalamine market share due to the growing awareness about the benefits of the drug. In addition, the presence of prominent pharmaceutical firms in the region is forecast to contribute to the market growth. Government funding and incentives are also forecast to surge market growth in the coming years. In addition, the growing prevalence of disease and growing geriatric population will benefit the regional mesalamine market during the study period.

Competitors in the Market

• Mylan N.V.
• Teva Pharmaceuticals
• Ferring B.V.
• Allergan
• Bausch Health Companies Incorporated (Salix Pharmaceutical).
• Zydus Cadila
• Cosmo Pharmaceuticals
• Tillotts Pharma AG
• Shire plc
• Pfizer Incorporated
• Norga Pharma
• AstraZeneca
• Abbvie Incorporated
• Takeda Pharmaceuticals
• Johnson and Johnson
• Boehringer Ingelheim GmbH
• Sandoz Mesalamine
• Cipla
• Synmosa Biopharma Corporation
• Lunan Better Pharmaceuticals
• Merck & Co
• Novartis AG
• Other Prominent Players

Market Segmentation

The global mesalamine market segmentation focuses on Dosage Form, Application, and Region.

Based on the dosage form, the mesalamine market is segmented into –

• Capsule
• Tablets

Based on application, the mesalamine market is segmented into –

• Ulcerative colitis
• Crohn's disease
• Other bowel inflammatory diseases

Based on region, the mesalamine market is segmented into –

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America